%0 Journal Article
%A Tian, Yu
%A Kim, Andre E
%A Bien, Stephanie A
%A Lin, Yi
%A Qu, Conghui
%A Harrison, Tabitha
%A Carreras-Torres, Robert
%A Díez-Obrero, Virginia
%A Dimou, Niki
%A Drew, David A
%A Hidaka, Akihisa
%A Huyghe, Jeroen R
%A Jordahl, Kristina M
%A Morrison, John
%A Murphy, Neil
%A Obón-Santacana, Mireia
%A Ulrich, Cornelia M
%A Ose, Jennifer
%A Peoples, Anita R
%A Ruiz-Narvaez, Edward A
%A Shcherbina, Anna
%A Stern, Mariana
%A Su, Yu-Ru
%A van Duijnhoven, Franzel J B
%A Arndt, Volker
%A Baurley, James
%A Berndt, Sonja I
%A Bishop, D Timothy
%A Brenner, Hermann
%A Buchanan, Daniel D
%A Chan, Andrew T
%A Figueiredo, Jane C
%A Gallinger, Steven
%A Gruber, Stephen B
%A Harlid, Sophia
%A Hoffmeister, Michael
%A Jenkins, Mark A
%A Joshi, Amit D
%A Keku, Temitope O
%A Larsson, Susanna C
%A Le Marchand, Loic
%A Li, Li
%A Giles, Graham G
%A Milne, Roger L
%A Nan, Hongmei
%A Nassir, Rami
%A Ogino, Shuji
%A Budiarto, Arif
%A Platz, Elizabeth A
%A Potter, John D
%A Prentice, Ross L
%A Rennert, Gad
%A Sakoda, Lori C
%A Schoen, Robert E
%A Slattery, Martha L
%A Thibodeau, Stephen N
%A Van Guelpen, Bethany
%A Visvanathan, Kala
%A White, Emily
%A Wolk, Alicja
%A Woods, Michael O
%A Wu, Anna H
%A Campbell, Peter T
%A Casey, Graham
%A Conti, David V
%A Gunter, Marc J
%A Kundaje, Anshul
%A Lewinger, Juan Pablo
%A Moreno, Victor
%A Newcomb, Polly A
%A Pardamean, Bens
%A Thomas, Duncan C
%A Tsilidis, Konstantinos K
%A Peters, Ulrike
%A Gauderman, W James
%A Hsu, Li
%A Chang-Claude, Jenny
%T Genome-Wide Interaction Analysis of Genetic Variants with Menopausal Hormone Therapy for Colorectal Cancer Risk.
%J Journal of the National Cancer Institute
%V 114
%N 8
%@ 0027-8874
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2022-01089
%P 1135-1148
%D 2022
%Z #EA:C020#LA:C020#  / 2022 Aug 8;114(8):1135-1148
%X The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk.We conducted a genome-wide gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen-only, and combined estrogen-progestogen therapy with CRC risk, among 28,486 postmenopausal women (11,519 cases and 16,967 controls) from 38 studies, using logistic regression, two-step method, and 2- or 3-degree-of-freedom (d.f.) joint test. A set-based score test was applied for rare genetic variants.The use of any MHT, estrogen-only and estrogen-progestogen were associated with a reduced CRC risk [odds ratio (OR) with 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35512400
%R 10.1093/jnci/djac094
%U https://inrepo02.dkfz.de/record/180090